Evidence map›Paper›PMID 41266588›Full record

ArticleScientific reports2025

Key domains involved in the interaction and assembly of the HCMV terminase complex.

C Gourin, C Lefèvre, T Flores, A Couvreux, S Alain, G Ligat, S Hantz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

C GourinINSERM, CHU Limoges, University of Limoges, RESINFIT, U1092, Limoges, 87000, France.
C LefèvreINSERM, CHU Limoges, University of Limoges, RESINFIT, U1092, Limoges, 87000, France.
T FloresUniv Toulouse, INSERM, CNRS, Infinity-Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
A CouvreuxINSERM, CHU Limoges, University of Limoges, RESINFIT, U1092, Limoges, 87000, France.
S AlainINSERM, CHU Limoges, University of Limoges, RESINFIT, U1092, Limoges, 87000, France.
G LigatUniv Toulouse, INSERM, CNRS, Infinity-Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France. gaetan.ligat@inserm.fr.
S HantzINSERM, CHU Limoges, University of Limoges, RESINFIT, U1092, Limoges, 87000, France. sebastien.hantz@unilim.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) causes life-threatening infections, particularly in immunocompromised patients. Letermovir targets the viral terminase complex (pUL56, pUL89, pUL51), essential for DNA packaging, but resistance mutations in pUL56 underline the need for new antiviral strategies. Targeting critical interaction domains within the complex, such as the pUL56 peptide

Indexed as

CytomegalovirusEndodeoxyribonucleasesViral ProteinsHEK293 CellsHumansModels, MolecularMutationProtein BindingProtein DomainsProtein Interaction Domains and MotifsViral Structural ProteinsVirus ReplicationEndodeoxyribonucleasesterminaseUL56 protein, cytomegalovirusUL89 protein, CytomegalovirusViral ProteinsViral Structural ProteinsHuman cytomegaloviruspUL56pUL89TerminasesTherapeutic targets

Identifiers

PMID41266588
PMCPMC12749448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.